Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 15/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27897076 | 0.86 | LCK (0.51) | LCKBTKCYP17A1CYP3A4CYP1A2 | |
| SCHEMBL26466318 | 0.83 | CYP17A1 (0.49) | LCKBTKCYP17A1CYP1A2 | |
| SCHEMBL21128380 | 0.81 | CYP17A1 (0.50) | LCKBTKCYP17A1CYP3A4CYP1A2 | |
| SCHEMBL527326 | 0.80 | CYP1A2 (0.43) | LCKBTKCYP17A1CYP3A4CYP1A2 | |
| SCHEMBL26463109 | 0.79 | CYP17A1 (0.46) | LCKBTKCYP17A1CYP1A2 | |
| SCHEMBL29988790 | 0.78 | TDO2 (0.49) | CYP17A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3421743 | 0.78 | TDO2 (0.49) | CYP17A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2206282 | 0.78 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CA | |
| SCHEMBL30839749 | 0.78 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CA | |
| SCHEMBL15784053 | 0.77 | LCK (0.46) | LCKBTKCYP17A1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | LCK 2998/4885BTK 1967/4885CYP17A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.